4.吴海鹰-转移性非小细胞肺癌的治疗

2016

ASCO转移性非小细胞肺癌治疗口头摘要报告会中山大学肿瘤医院

吴海鹰

整理Epidermal

growth

factor

receptor

genotyping

of

matched

urine,

plasma

and

tumor

tissue

from

non-small

cell

lung

cancer

patients

treated

with

rociletinibPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingRociletinib

Is

a

Covalent

Inhibitor

of

Mutant

EGFR,

Including

T790MPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingTIGER-X:

Safety

and

Efficacy

PopulationPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingTIGER-X:

Baseline

Demographics

and

Investigator-Assessed

Confirmed

ORR

(RECIST

v1.1)Presented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingTIGER-X:

Overall

SafetyPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingTIGER-X:

Tissue,

Plasma,

and

Urine

EGFR

<br

/>Test

PlatformsPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingQuantitative

and

Sensitive

BEAMing

Test

(Sysmex

Inostics)

Used

for

Plasma

EGFR

Mutation

TestingPresented

By

Heather

Wakelee

at

2016ASCO

Annual

Meetingtrovera

Quantitative

Next-Generation

Sequencing

Assays

for

Urine

EGFR

Mutation

Testing1Presented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingTIGER-X:

Sample

Types

Submitted

for

Pretreatment

<br

/>EGFR

TestingPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingPlasma

Detection

Is

Sensitive

and

Can

Complement

Tissue

T790M

TestingPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingUrine

Detection

Is

Equally

Sensitive

and

Can

Complement

Tissue

T790M

TestingPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingInvestigator-Assessed

Confirmed

Response

Rate

Is

Similar

for

T790M-Positive

Patients

Identified

by

Plasma,

Tissue,

and

Urine

TestPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingDuration

of

Response

and

Progression-Free

Survival:<br

/>Results

Independent

of

Sample

Type

Used

to

Identify

T790M

PositivityPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingDetection

of

T790M

in

Liquid

Biopsies

of

Patients

with

Distant

Metastatic

vs

Intrathoracic

DiseasePresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingConclusionsPresented

By

Heather

Wakelee

at

2016ASCO

Annual

MeetingOsimertinib

activity

in

patients

with

leptomeningeal

disease

from

non-small

cell

lung

cancer:

<br

/>updated

results

from

the

BLOOM

studyPresented

By

James

Yang

at

2016ASCO

Annual

MeetingLeptomeningeal

metastasesPresented

By

James

Yang

at

2016ASCO

Annual

MeetingBLOOM

study

design:

osimertinib

LM

cohort

1Presented

By

James

Yang

at

2016ASCO

Annual

MeetingPatient

demographics:

osimertinib

LM

cohort

1Presented

By

James

Yang

at

2016ASCO

Annual

MeetingSummary

of

adverse

eventsPresented

By

James

Yang

at

2016ASCO

Annual

MeetingOsimertinib

activity

across

LM

assessmentsPresented

By

James

Yang

at

2016ASCO

Annual

MeetingCase

study:

63

year

old

Korean

male

patientPresented

By

James

Yang

at

2016ASCO

Annual

MeetingConclusionsPresented

By

James

Yang

at

2016ASCO

Annual

MeetingPhase

I

study

(BLOOM)

of

AZD3759,

a

CNS

penetrable

EGFR

inhibitor,

for

the

treatment

of

non-small-cell

lung

cancer

(NSCLC)

with

brain

metastasis

(BM)

and

leptomeningealmetastasis

(LM)Presented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingIntroductionPresented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingBLOOM

study

design

–

AZD3759

dose

escalationPresented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingPatient

demographicsPresented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingSummary

of

AEs

and

dose

interruption/reductionPresented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingClinical

pharmacokinetics

of

AZD3759

and

metabolite

(AZ’1168)*Presented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingAnti-tumor

activityPresented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingSlide

11Presented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingSlide

12Presented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingConclusionPresented

By

Myung-Ju

Ahn

at

2016ASCO

Annual

MeetingLocal

Consolidative

Therapy

(LCT)

Improves

Progression-Free

Survival

(PFS)

in

Patients

with

Oligometastatic

Non-Small

Cell

Lung

Cancer

(NSCLC)

who

do

not

Progress

afterFront

Line

Systemic

Therapy

(FLST):

Results

of

a

Multi-Institutional

Phase

II

Randomized

StudyPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingIntroductionPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingTrial

DesignPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingTrial

DesignPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingTrial

DesignPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingStatistical

ConsiderationsPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingCONSORT

DiagramPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingPatient

CharacteristicsPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingPFS

Outcomes

(updated

data)Presented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingOverall

SurvivalPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingConclusionsPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingConclusionsPresented

By

Daniel

Gomez

at

2016ASCO

Annual

MeetingWeekly

Paclitaxel

plus

Bevacizumab

versus

Docetaxel

as

Second

or

Third-line

Treatment

in

Advanced

Non-Squamous

Non-Small

Cell

Lung

Cancer

(NSCLC):

Results

from

thePhase

III

Study

IFCT-1103

ULTIMATEPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingBackgroundPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingULTIMATE

:

study

designPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingEndpointsPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingKey

eligibility

criteriaPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingBaseline

characteristicsPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingHematological

ToxicityPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingNon-Hematological

ToxicityPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingResponse

Rate

at

8

weeksPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingProgression-Free

SurvivalPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingOverall

SurvivalPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingPost-discontinuation

treatmentsPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingConclusionsPresented

By

Alexis

Cortot

at

2016ASCO

Annual

MeetingBrigatinib

in

Patients

With

Crizotinib-Refractory

ALK+

Non–Small

Cell

Lung

Cancer:

First

Report

of

Efficacy

and

Safety

From

a

Pivotal

Randomized

Phase

2

Trial

(ALTA)Presented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingBackgroundPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingBrigatinib

Exhibits

a

Pan-Inhibitory

Preclinical

Profile

Against

ALK

Resistance

MutantsPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingALTA:

Randomized

Dose

Evaluation

of

BrigatinibPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingDemographics

and

Baseline

CharacteristicsPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingObjective

Response

Rates

in

Crizotinib-Resistant

Patients

by

ArmPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingBrigatinib

Antitumor

Activity

by

ArmPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingPFS

by

ArmPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingIRC-Assessed

Intracranial

Response

RatesPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingIntracranial

PFS

by

ArmPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingTreatment-Emergent

Adverse

EventsPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingConclusionsPresented

By

Dong-Wan

Kim

at

2016ASCO

Annual

MeetingAlectinib

versus

Crizotinib

in

ALK

Inhibitor

Naïve

ALK-Positive

Non-Small

Cell

Lung

Cancer:<br

/>

Primary

Results

from

the

J-ALEX

StudyPresented

By

Hiroshi

Nokihara

at

2016

ASCO

Annual

MeetingBackgroundPresented

By

Hiroshi

Nokihara

at

2016

ASCO

Annual

MeetingAlectinib:

Potent,

Highly

Selecti